A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer

Summary

A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.

Timeline

Start

2022-11-03

Primary completion

2025-07-31

Completion

2026-08

Outcome

Met primary endpoint

release “64% of response-evaluable patients (9 of 14) achieved complete or partial ablation of a treated tumour or tumour segment, meeting the primary efficacy endpoint” qbiotics.com ↗

Drugs

Indications